Literature DB >> 18519762

Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion.

Georg Sauer1, Nicole Schneiderhan-Marra, Cornelia Kazmaier, Kathrin Hutzel, Karin Koretz, Rainer Muche, Rolf Kreienberg, Thomas Joos, Helmut Deissler.   

Abstract

PURPOSE: Identification of molecular characteristics that are useful to define subgroups of patients fitting into differential treatment schemes is considered a most promising approach in cancer research. In this first study of such type, we therefore investigated the potential of multiplexed sandwich immunoassays to define protein expression profiles indicative of clinically relevant properties of malignant tumors. EXPERIMENTAL
DESIGN: Lysates prepared from large core needle biopsies of 113 invasive breast carcinomas were analyzed with bead-based miniaturized sandwich immunoassays specific for 54 preselected proteins.
RESULTS: Five protein concentrations [fibroblast growth factor-2 (FGF-2), Fas, Fas ligand, tissue inhibitor of metalloproteinase-1, and RANTES] were significantly different in the groups of patients with or without axillary lymph node metastasis. All 15 protein parameters that resulted in P values <0.2 and other diagnostic information [estrogen receptor (ER) status, tumor size, and histologic grading] were analyzed together by multivariate logistic regression. This yielded sets of five (FGF-2, Fas, Fas ligand, IP10, and PDGF-AB/BB) or six (ER staining intensity, FGF-2, Fas ligand, matrix metalloproteinase-13, PDGF-AB/BB, and IP10) parameters for which receiver-operator characteristic analyses revealed high sensitivities and specificities [area under curve (AUC) = 0.75 and AUC = 0.83] to predict the nodal status. A similar analysis including all identified parameters of potential value (15 proteins, ER staining intensity, T) without selection resulted in a receiver-operator characteristic curve with an AUC of 0.87.
CONCLUSION: We clearly showed that this approach can be used to quantify numerous proteins from breast biopsies accurately in parallel and define sets of proteins whose combined analyses allow the prediction of nodal involvement with high specificity and sensitivity.

Entities:  

Mesh:

Year:  2008        PMID: 18519762     DOI: 10.1158/1078-0432.CCR-07-4802

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Molecular indicators of non-sentinel node status in breast cancer determined in preoperative biopsies by multiplexed sandwich immunoassays.

Authors:  Georg Sauer; Nicole Schneiderhan-Marra; Rainer Muche; Karin Koretz; Cornelia Kazmaier; Rolf Kreienberg; Thomas Joos; Helmut Deissler
Journal:  J Cancer Res Clin Oncol       Date:  2011-04-24       Impact factor: 4.553

Review 2.  Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer.

Authors:  Ayesha Khalid; Joy Wolfram; Ilaria Ferrari; Chaofeng Mu; Junhua Mai; Zhizhou Yang; Yuliang Zhao; Mauro Ferrari; Xiaojing Ma; Haifa Shen
Journal:  Mini Rev Med Chem       Date:  2015       Impact factor: 3.862

3.  The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines.

Authors:  Adit Ben-Baruch
Journal:  Cancer Microenviron       Date:  2011-12-22

4.  Strong and oriented immobilization of single domain antibodies from crude bacterial lysates for high-throughput compatible cost-effective antibody array generation.

Authors:  Klervi Even-Desrumeaux; Daniel Baty; Patrick Chames
Journal:  Mol Biosyst       Date:  2010-09-21

5.  Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics.

Authors:  Jaime A Espinoza; Shakila Jabeen; Richa Batra; Elena Papaleo; Vilde Haakensen; Vera Timmermans Wielenga; Maj-Lis Møller Talman; Nils Brunner; Anne-Lise Børresen-Dale; Pavel Gromov; Åslaug Helland; Vessela N Kristensen; Irina Gromova
Journal:  Oncoimmunology       Date:  2016-10-24       Impact factor: 8.110

6.  Mechanisms regulating the secretion of the promalignancy chemokine CCL5 by breast tumor cells: CCL5's 40s loop and intracellular glycosaminoglycans.

Authors:  Gali Soria; Yaeli Lebel-Haziv; Marcelo Ehrlich; Tsipi Meshel; Adva Suez; Edward Avezov; Perri Rozenberg; Adit Ben-Baruch
Journal:  Neoplasia       Date:  2012-01       Impact factor: 5.715

7.  µFBI: a microfluidic bead-based immunoassay for multiplexed detection of proteins from a µL sample volume.

Authors:  Xiaobo Yu; Michael Hartmann; Quan Wang; Oliver Poetz; Nicole Schneiderhan-Marra; Dieter Stoll; Cornelia Kazmaier; Thomas O Joos
Journal:  PLoS One       Date:  2010-10-01       Impact factor: 3.240

Review 8.  CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

Authors:  Dandan Lv; Yan Zhang; Ha-Jeong Kim; Lixing Zhang; Xiaojing Ma
Journal:  Cell Mol Immunol       Date:  2013-02-04       Impact factor: 11.530

9.  A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells.

Authors:  Yan Zhang; Dandan Lv; Ha-Jeong Kim; Robert A Kurt; Wen Bu; Yi Li; Xiaojing Ma
Journal:  Cell Res       Date:  2012-12-25       Impact factor: 25.617

10.  Multiplexed quantification of estrogen receptor and HER2/Neu in tissue and cell lysates by peptide immunoaffinity enrichment mass spectrometry.

Authors:  Regine M Schoenherr; Jeffrey R Whiteaker; Lei Zhao; Richard G Ivey; Mary Trute; Jacob Kennedy; Uliana J Voytovich; Ping Yan; Chenwei Lin; Amanda G Paulovich
Journal:  Proteomics       Date:  2012-04       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.